sever
acut
respiratori
syndrom
sar
newli
emerg
readili
transmiss
predominantli
pneumon
diseas
caus
novel
coronaviru
refer
steroid
ribavirin
march
call
upon
laboratori
nine
countri
join
network
multicent
research
etiolog
sar
april
announc
new
coronaviru
never
seen
human
anim
identifi
caus
sar
steroid
ribavirin
use
empir
outset
epidem
hong
kong
toronto
result
experi
et
al
lapinski
hawryluck
propos
sar
treatment
protocol
use
combin
regimen
steroid
ribavirin
corticosteroid
commonli
use
immunomodulatori
agent
variou
critic
diseas
modul
larg
number
inflammatori
cytokin
play
key
role
immun
homeostasi
although
valu
corticosteroid
therapi
nonvir
adult
respiratori
distress
syndrom
ard
controversi
report
shown
effect
corticosteroid
treat
measl
pneumonia
viral
pneumonia
complic
varicella
ribavirin
purin
nucleosid
analogu
hinder
replic
varieti
rna
virus
although
precis
mechan
action
still
shown
ribavirin
use
combin
interferon
treat
hepat
c
viru
infect
monotherapi
lassa
fever
viru
infect
sever
respiratori
syncyti
viru
rsv
infect
effect
ribavirin
murin
hepat
viru
belong
group
ii
coronavirida
demonstr
anim
model
vitro
inhibit
rsv
influenza
virus
parainfluenza
virus
achiev
ribavirin
concentr
oral
dose
mg
yield
peak
plasma
level
intraven
dose
mg
result
mean
plasma
concentr
tabl
summar
clinic
report
outlin
treatment
regimen
describ
clinic
outcom
sar
patient
among
steroid
intraven
hydrocortison
hc
mgday
mgkg
per
day
methylprednisolon
mpsl
mgday
mgkg
per
day
first
administ
patient
condit
worsen
clinic
puls
dose
mpsl
gday
usual
ad
although
studi
case
use
steroid
restrict
report
outcom
poor
tabl
no
demonstr
steroid
could
lead
earli
improv
term
fever
subsid
less
lung
infiltr
chest
xray
better
oxygen
rational
use
corticosteroid
base
find
paradox
clinic
deterior
occur
despit
fall
viral
load
igg
seroconvers
take
place
furthermor
lung
patholog
show
pronounc
increas
alveolar
macrophag
hemophagocytosi
impli
immun
system
hyperact
due
cytokin
dysregul
gener
use
steroid
sar
regard
benefici
although
time
dosag
durat
treatment
controversi
et
al
propos
steroid
administr
commenc
extens
bilater
chest
radiograph
involv
seen
chest
radiograph
involv
high
fever
persist
day
clinic
chest
radiograph
laboratori
find
suggest
worsen
condit
oxygen
satur
room
air
time
convinc
whether
sar
diagnosi
confirm
revers
transcriptasepolymeras
chain
reaction
rtpcr
test
diseas
may
selflimit
sar
patient
diseas
sever
depend
patient
age
underli
immun
statu
tooearli
steroid
administr
may
impair
contain
viral
replic
immunosuppress
effect
steroid
howev
condit
patient
deterior
quickli
thu
cours
diseas
must
observ
care
recommend
dosag
steroid
vari
greatli
among
hospit
studi
ho
et
al
compar
efficaci
initi
use
lowdos
highdos
steroid
regimen
tabl
suggest
highdos
puls
mpsl
treatment
efficaci
equal
safe
compar
lowdosag
regimen
et
al
report
mgkg
per
day
dose
mpsl
fail
control
fever
thu
increas
initi
dose
mgkg
per
day
administ
puls
mpsl
rescu
therapi
patient
condit
deterior
also
show
mpsl
step
day
long
use
dose
stepdown
symptom
rebound
dose
level
continu
day
tabl
anoth
studi
use
highdos
steroid
although
combin
interferon
upon
worsen
clinic
criteria
tabl
report
compar
low
mortal
rate
steroid
dosag
chosen
counterbal
degre
hyperimmun
adjust
accord
individu
age
immunocompet
diseas
sever
also
recogn
prolong
use
highdos
steroid
concern
immunosuppress
may
detriment
patient
encourag
secondari
sepsi
recent
news
circul
insid
china
indic
quit
peopl
contract
sar
found
suffer
avascular
necrosi
known
occur
side
effect
strong
dose
corticosteroid
determin
optim
time
dosag
durat
steroid
treatment
random
control
trial
done
although
dosag
administr
rout
ribavirin
quit
divers
ribavirin
administr
appar
reduc
intratrach
intub
mortal
rate
tabl
booth
et
al
use
highdos
intraven
ribavirin
report
mortal
rate
tabl
howev
attribut
signific
toxic
ribavirin
includ
hemolyt
anemia
electrolyt
disturb
compar
trial
conduct
zhao
et
al
show
ribavirin
least
given
low
dose
basic
ineffect
tabl
furthermor
use
ribavirin
attract
consider
skeptic
exhibit
vitro
efficaci
sarscov
postmortem
examin
tissu
show
sarscov
erad
ribavirin
therapi
quantit
rtpcr
monitor
nasopharyng
viral
load
also
suggest
substanti
vivo
antivir
effect
drug
howev
sinc
suggest
ribavirin
benefici
immunomodulatori
effect
welldesign
random
control
studi
need
draw
firm
conclus
interferon
famili
cytokin
import
cellular
immun
respons
shown
partli
effect
anim
human
coronavirus
vitro
examin
interferon
sarscov
recent
carri
use
interferon
interferon
interferon
interferon
b
found
potent
interferon
remain
effect
viral
infect
although
potenti
differ
interferon
b
debat
use
interferon
treatment
sar
limit
interferon
combin
steroid
immunoglobulin
thymic
peptid
efficaci
ascertain
preliminari
data
canada
faster
recoveri
observ
anecdot
small
canadian
seri
consensu
interferon
share
homolog
interferon
homolog
interferon
use
result
suggest
interferon
promis
test
futur
sar
treatment
trial
lopinavirritonavir
coformul
kaletra
proteas
inhibitor
prepar
use
treat
human
immunodefici
viru
hiv
infect
use
combin
ribavirin
hong
kong
hospit
hope
would
inhibit
coronavir
proteas
thu
block
process
viral
replicas
polyprotein
prevent
replic
viral
rna
preliminari
result
suggest
use
lopinavirritonavir
simultan
ribavirin
corticosteroid
might
reduc
intub
mortal
rate
especi
administ
earli
thu
appear
worthwhil
conduct
control
studi
promis
class
drug
glycyrrhizin
use
treatment
chronic
hepat
rel
nontox
test
vitro
found
activ
agent
sarscov
inhibit
viral
adsorpt
penetr
effect
administ
viral
adsorpt
period
postul
mechan
action
mediat
nitrou
oxid
pathway
gamma
immunoglobulin
use
hospit
china
hong
kong
howev
therapi
corticosteroid
often
use
concomitantli
effect
sar
remain
uncertain
convalesc
plasma
collect
recov
patient
also
remain
evalu
shown
tabl
sar
patient
eventu
requir
intub
mechan
ventil
owe
sever
respiratori
failur
noninvas
posit
pressur
ventil
nippv
commonli
employ
mani
chines
hospit
found
avert
need
intub
invas
ventil
twothird
sar
patient
deterior
nippv
given
use
continu
posit
airway
pressur
cm
h
bilevel
pressur
support
inspiratori
posit
airway
pressur
cm
h
expiratori
posit
airway
pressur
cm
h
although
nippv
use
infect
risk
associ
aerosol
gener
hamper
use
mani
hospit
highli
rigor
infect
control
measur
addit
standard
infect
control
measur
recommend
aerosolgener
procedur
util
ventilatori
manag
patient
sar
differ
patient
ard
pressur
volum
control
ventil
employ
tidal
volum
kept
low
mlkg
bodi
weight
plateau
pressur
kept
cm
h
posit
endexpiratori
pressur
also
titrat
low
valu
possibl
maintain
oxygen
pneumothorax
pneumomediastinum
known
complic
sar
even
without
assist
posit
pressur
ventil
high
rate
barotrauma
report
experienc
sar
outbreak
japan
therefor
domest
inform
sar
treatment
thu
recent
visit
tan
tock
seng
hospit
singapor
sunnybrook
women
colleg
health
centr
toronto
canada
mani
sar
patient
treat
ask
physician
charg
impress
effect
variou
sar
treatment
got
respons
follow
find
ribavirin
clinic
benefit
intend
use
futur
steroid
use
cautious
take
account
diseas
sever
patient
diseas
selflimit
thu
difficult
recommend
establish
treatment
protocol
time
pend
develop
vaccin
new
drug
specif
sar
result
wellconduct
random
control
studi
suffici
number
case
reli
exist
treatment
modal
describ
discuss
review
